Abstract
Esophageal cancer is the 8th-most common cancer and the 6th-most common cause of cancer-related deaths worldwide; 5-year overall survival is 18%. Patients with advanced esophageal squamous cell carcinoma (advESCC) most commonly receive systemic therapy. Platinum (Pt) and fluoropyrimidine (FP) doublet is the most common standard first line (1L) regimen. This study describes global and regional treatment patterns and outcomes, including healthcare resource utilization (HCRU) of patients with advESCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
